Kymera Investor Presentation Deck
November 2023, 41 slides
  1. Kymera
  2. Related Decks
  3. Investor Presentation Decks
inventing new medicines | Kymera
forward looking statements | Kymera
overview | Kymera
recent accomplishments a a | Kymera
a differentiated approach to | Kymera
clinical and near term clinical pipeline of novel protein degraders | Kymera
| Kymera
degrading best approach to block driven inflammation | Kymera
degrader best in class potential in immune inflammation an | Kymera
phase data supports phase advancement | Kymera
healthy volunteer study robust and sustained degradation leading to broad impact | Kymera
plasma and degradation in and patients dosed for days are comparable to | Kymera
disease relevant genes in skin lesions in of evaluable and patients at day | Kymera
significant reductions in an counts leading to responses and significant reductions in pain and | Kymera
showed meaningful signs of clinical activity in comparing favorably to placebo and soc | Kymera
significant reduction in score and pruritus | Kymera
showed meaningful signs of clinical activity in comparing favorably to placebo and soc | Kymera
adverse events related to occurring in patient | Kymera
oral agent with potential to achieve broad well tolerated anti inflammatory effect in multiple diseases | Kymera
sar ongoing phase trials in and hidradenitis atopic dermatitis | Kymera
| Kymera
degrader in oncology | Kymera
highly active on intermittent dosing regimens | Kymera
| Kymera
overall safety profile as of may | Kymera
consistent plasma across the evaluated dose levels as of may | Kymera
up to mean maximum nearing desired degradation profile at as of may | Kymera
achieved pathway inhibition and of inflammatory in blood | Kymera
ash abstract summary | Kymera
desired translation of and safety preclinical diverse indications | Kymera
| Kymera
potent degrader and best in class stabilizer benefits of degradation | Kymera
is superior to small molecule inhibitors | Kymera
potently degrades leading to pathway impact and activity superior to in all and models | Kymera
phase a study design and arm a enrollment status | Kymera
of plasma shows target engagement by at dose levels and | Kymera
initial clinical activity demonstrated in phase a sarcoma | Kymera
phase a safety update | Kymera
emerging clinical data support therapeutic hypothesis for degrader | Kymera
upcoming milestones and events immunology oncology | Kymera
| Kymera
See More
Kymera
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Tumor
Plasma
Blood
Oncology
Solid tumor
Recent decks by Kymera
Investor Presentation
December 2023
Investor Presentation
August 2023
Investor Presentation
June 2023
Results
December 2022
See all presentations by Kymera (7 decks)
Related decks
Nuvectis Pharma
Investor Presentation
August 2023
BioNTech
Results
August 2022
BioNTech
Results
May 2021
Alkermes
Investor Presentation
October 2023
Nuvectis Pharma
Investor Presentation
December 2023
Nuvectis Pharma
Investor Presentation
July 2023
BioNTech
Results
March 2021
Genprex
Investor Presentation
October 2022
Recent decks by Kymera
See all presentations (7 decks)
Investor Presentation
December 2023
Investor Presentation
August 2023
Investor Presentation
June 2023
Results
December 2022
Nuvectis Pharma
Investor Presentation
August 2023
BioNTech
Results
August 2022
BioNTech
Results
May 2021
Alkermes
Investor Presentation
October 2023
Nuvectis Pharma
Investor Presentation
December 2023
Nuvectis Pharma
Investor Presentation
July 2023
BioNTech
Results
March 2021
Genprex
Investor Presentation
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io